S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
Laser breakthrough could send stock soaring 2,467% (Ad)
3 Mid Caps You Haven't Heard Of But Need To Know About
Even at $2,000+ Per Share, These 3 Stocks Are Deals
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Will NIO Partake In China's Economic Awakening?
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
Tax Software Specialist Vertex In Buy Zone After Base Breakout
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
Laser breakthrough could send stock soaring 2,467% (Ad)
3 Mid Caps You Haven't Heard Of But Need To Know About
Even at $2,000+ Per Share, These 3 Stocks Are Deals
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Will NIO Partake In China's Economic Awakening?
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
Tax Software Specialist Vertex In Buy Zone After Base Breakout
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
Laser breakthrough could send stock soaring 2,467% (Ad)
3 Mid Caps You Haven't Heard Of But Need To Know About
Even at $2,000+ Per Share, These 3 Stocks Are Deals
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Will NIO Partake In China's Economic Awakening?
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
Tax Software Specialist Vertex In Buy Zone After Base Breakout
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
Laser breakthrough could send stock soaring 2,467% (Ad)
3 Mid Caps You Haven't Heard Of But Need To Know About
Even at $2,000+ Per Share, These 3 Stocks Are Deals
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Will NIO Partake In China's Economic Awakening?
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
Tax Software Specialist Vertex In Buy Zone After Base Breakout

NeuroPace (NPCE) Price Target & Analyst Ratings

$4.08
-0.07 (-1.69%)
(As of 06/9/2023 ET)
Compare
Today's Range
$4.07
$4.11
50-Day Range
$3.98
$5.13
52-Week Range
$1.22
$6.49
Volume
7,712 shs
Average Volume
8,469 shs
Market Capitalization
$103.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.25

NeuroPace Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 2 Analyst Ratings

Consensus Analyst Price Target

$7.25
77.70% Upside
High Prediction$10.00
Average Prediction$7.25
Low Prediction$4.50
TypeCurrent
6/10/22 to 6/10/23
1 Month Ago
5/11/22 to 5/11/23
3 Months Ago
3/12/22 to 3/12/23
1 Year Ago
6/10/21 to 6/10/22
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
2 Buy rating(s)
3 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$7.25$7.25$9.17$14.40
Predicted Upside77.70% Upside64.96% Upside59.98% Upside30.81% Upside
Get NeuroPace Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for NPCE and its competitors with MarketBeat's FREE daily newsletter.


NPCE Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

NPCE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

NeuroPace Stock vs. The Competition

TypeNeuroPaceMedical CompaniesS&P 500
Consensus Rating Score
2.00
2.66
2.48
Consensus RatingHoldBuyHold
Predicted Upside77.70% Upside1,154.28% Upside247.61% Upside
News Sentiment RatingVery Positive News
Positive News
Positive News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/3/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetUnderweight$2.50 ➝ $4.50+30.43%
2/22/2023Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$10.00+87.27%
(Data available from 6/10/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












NPCE Price Target - Frequently Asked Questions

What is NeuroPace's consensus rating and price target?

According to the issued ratings of 2 analysts in the last year, the consensus rating for NeuroPace stock is Hold based on the current 1 sell rating and 1 buy rating for NPCE. The average twelve-month price prediction for NeuroPace is $7.25 with a high price target of $10.00 and a low price target of $4.50. Learn more on NPCE's analyst rating history.

Do Wall Street analysts like NeuroPace more than its competitors?

Analysts like NeuroPace less than other Medical companies. The consensus rating for NeuroPace is Hold while the average consensus rating for medical companies is Buy. Learn more on how NPCE compares to other companies.

Does NeuroPace's stock price have much upside?

According to analysts, NeuroPace's stock has a predicted upside of 64.96% based on their 12-month price targets.


Stock Ratings Reports and Tools

This page (NASDAQ:NPCE) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -